Sofinnova Partners raises EUR 300M for Fund VIII

France's Sofinnova Partners closed its Sofinnova Capital VIII fund at EUR 300 million ($324.6 million), the maximum cap for the fund and above its initial target of EUR 250 million ($270.5 million).

Sofinnova intends to invest the fund in early stage biopharma and medical device companies. About two-thirds of the fund will be invested in Europe, with the remainder primarily invested in the U.S. Investors in the fund included pension funds, fund of funds, family offices and insurance companies from Europe and North America. ...